Abstract:"Resveratrol has differential effects on neuronal and glial MMP release" As shown above, resveratrol inhibits basal and LPS‐stimulated release of MMP2/9 from cultured glia, which may promote BBB injury, but spares basal and NMDA‐stimulated MMP‐9 release from neurons, which may promote neuronal plasticity. Of interest, however, resveratrol reduces PNN component expression from both culture types. Resveratrol, a naturally occurring polyphenol that activates sirtuin 1 (SIRT1), has been shown to reduce overall levels of matrix metalloprotease‐9 (MMP‐9) in cerebrospinal fluid (CSF) samples from patients with Alzheimer's dementia (AD). Depending on the site of release, however, MMP‐9 has the potential to improve or impair cognition. In particular, its release from microglia or pericytes proximal to the blood brain barrier can damage the basement membrane, while neuronal activity‐dependent release of this protease from glutamatergic neurons can instead promote dendritic spine expansion and long‐term potentiation of synaptic plasticity. In the present study, we test the hypothesis that resveratrol reduces overall MMP‐9 levels in CSF samples from patients with APOE4, an allele associated with increased glial inflammation. We also examine the possibility that resveratrol reduces inflammation‐associated MMP release from cultured glia but spares neuronal activity‐dependent release from cultured cortical neurons. We observe that resveratrol decreases overall levels of MMP‐2 and MMP‐9 in CSF samples from AD patients. Resveratrol also reduces CSF levels of tissue inhibitor of metalloproteinases‐1 (TIMP‐1), glial‐derived protein that restricts long‐term potentiation of synaptic transmission, in individuals homozygous for APOE4. Consistent with these results, we observe that resveratrol reduces basal and lipopolysaccharide (LPS)‐stimulated MMP and TIMP‐1 release from cultured microglia and astrocytes. In contrast, however, resveratrol does not inhibit release of MMP‐9 from cortical neurons. Overall, these results are consistent with the possibility that while resveratrol reduces potentially maladaptive MMP and TIMP‐1 release from activated glia, neuroplasticity‐promoting MMP release from neurons is spared. In contrast, resveratrol reduces release of neurocan and brevican, extracellular matrix components that restrict neuroplasticity, from both neurons and glia. These data underscore the diversity of resveratrol's actions with respect to affected cell types and molecular targets and also suggest that further studies may be warranted to determine if its effects on glial MMP release could make it a useful adjunct for AD‐ and/or anti‐amyloid therapy‐related damage to the blood brain barrier.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer's Disease Inflammation

A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer's Amyloid-β-Induced Oxidative Stress, Mitochondrial Dysfunction, and Cell Senescence Through Upregulating SIRT3.

Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy

Resveratrol Attenuates Subacute Systemic Inflammation-Induced Spatial Memory Impairment Via Inhibition of Astrocyte Activation and Enhancement of Synaptophysin Expression in the Hippocampus.

Neuroprotective Effect of Resveratrol via Activation of Sirt1 Signaling in a Rat Model of Combined Diabetes and Alzheimer's Disease.

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Resveratrol Inhibits Β-Amyloid-induced Neuronal Apoptosis Through Regulation of SIRT1-ROCK1 Signaling Pathway.

Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease

Resveratrol-Selenium Nanoparticles Alleviate Neuroinflammation and Neurotoxicity in a Rat Model of Alzheimer’s Disease by Regulating Sirt1/miRNA-134/GSK3β Expression

Resveratrol As a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer’s Disease

Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by β-amyloid through activation of SIRT1/Akt1 pathway.

Dihydro‐resveratrol ameliorates NLRP3 inflammasome‐mediated neuroinflammation via Bnip3‐dependent mitophagy in Alzheimer's disease

Resveratrol Attenuates Oxidative Damage Through Activating Mitophagy in an in Vitro Model of Alzheimer's Disease.

Research Progress on Alzheimer's Disease and Resveratrol

Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy

Neuronal SIRT1 Activation As a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction.

Neuroprotective effects of resveratrol through modulation of PI3K/Akt/GSK‐3β pathway and metalloproteases

Resveratrol and Alzheimer's Disease: Mechanistic Insights

Treatment with Resveratrol Reduces Bone Fracture Risk Associated with Neurodegenerative Disease